Taipei Medical University Institutional Repository:Item 987654321/59433
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45069/58245 (77%)
造訪人次 : 2354820      線上人數 : 173
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/59433


    題名: 通過QSD奈米過濾膜所純化之血小板裂解液可維持細胞擴展能力並應用於再生醫學
    Platelet lysate-supplemented growth media purified through QyuSpeed D device maintains the capacity to stimulate cell expansion for regenerative medicine applications
    作者: 高瑀君
    Kao, Yu-Chun
    貢獻者: 白台瑞
    關鍵詞: 人血小板裂解物;QyuSpeed D;臍帶血間充質幹細胞;生長因子;細胞培養
    Human Platelet-Lysate;HPL;QyuSpeed D (QSD);Wharton jelly mesenchymal stem cells;WJMSC;Growth factors;Cell culture
    日期: 2015-07-08
    上傳時間: 2020-08-28 11:38:31 (UTC+8)
    摘要: Background: Human platelet lysates (HPL) can replace fetal bovine serum (FBS) for clinical-grade ex vivo expansion of cells, including mesenchymal stem cells (MSC). HPL contains platelet-derived growth factors that support cell growth and proliferation. HPL avoids the immunological and infectious risks associated with xenogenic FBS materials. However, in spite of the safety nets in place for donors screening and donation testing, infectious agents, including viruses and prions, can contaminate HPL. Therefore, HPL manufacturing processes should preferably undergo virus and prion reduction steps to ensure optimal pathogen safety. Recently, a new anion-exchange hollow-fiber chromatographic filtration membrane (QyuSpeed D, QSD) was shown to remove prions from growth media containing 10% FBS. We hypothesized that such QSD device could be used for removing pathogens from HPL.
    Aims: Determine whether growth media supplemented with HPL could be filtered through QSD filtration membrane under conditions (a) not affecting ex vivo cell expansion capacity and (b) removing blood-borne pathogens.
    Materials and Methods: HPL batches were prepared from various types of platelet concentrates subjected to 3 freeze/thaw cycles, “serum-converted” by calcium chloride, and centrifuged. Growth media were supplemented with 10% HPL and ca. 50 mL, or more, filtered through 0.6 mL QSD hollow fiber. HPL-supplemented growth media composition was determined by total protein assay, SDS-PAGE, growth factors ELISA assay and chemical analysis. Capacity of HPL-growth media, prior to or after QSD filtration, to support cell growth was compared using Chinese hamster ovary cells, gingival fibroblasts and periodontal ligament primary cells, and Wharton jelly cord blood (WJ) MSC. Cell expansion was evaluated by microscopy, cell counting, and MTT viability assays. Membrane markers were studied by flow cytometry. Doubling time and differentiation capacity of WJMSCs into adipogenic, osteogenic and chondrogenic lineages were determined. QSD removal capacity for prions and viruses was tested (duplicate runs each) with 97.4 ± 1.9 mL of growth medium containing 10% HPL after spiking with strain 263K hamster adapted scrapie (microsomal/cytosolic fraction) or Porcine Parvovirus (PPV), respectively. A Western blot assay was used for detecting PrPSc as a surrogate marker for infectivity. PPV infectivity was assessed by TCID50 infectivity assay on PK13 cells.
    Results: QSD filtration did not induce detectable adverse effect on the chemical, protein and growth factor composition of culture media supplemented with 10% HPL, nor on the growth and viability of the four cells evaluated. Mean reduction factors (logs) achieved by QSD were ≥ 5.42 ± 0.44 for 2% PPV and ≥ 3.47 for 2% 263K for the whole flow-through volume (100 mL).
    Summary/conclusions: HPL-supplemented growth media can be filtered through QSD anion-exchange hollow fiber membrane to remove prions and PPV under conditions that do not affect the capacity of HPL-growth media to stimulate ex vivo expansion of various cells, including MSC. This study opens the way to novel HPL-supplemented growth media with preserved capacity to support cell expansion, while also improving the level of pathogen safety for applications in cell therapy or in the production of therapeutic protein products made by recombinant technologies using mammalian cells.
    描述: 碩士
    指導教授:白台瑞
    委員:陳建中
    委員:曾靖孋
    資料類型: thesis
    顯示於類別:[生醫材料暨組織工程研究所] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML110檢視/開啟


    檢視Licence

    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋